Your browser is no longer supported. Please, upgrade your browser.
Settings
ALDX Aldeyra Therapeutics, Inc. daily Stock Chart
ALDX [NASD]
Aldeyra Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.75 Insider Own4.90% Shs Outstand30.12M Perf Week10.89%
Market Cap201.42M Forward P/E- EPS next Y-1.41 Insider Trans234.06% Shs Float22.60M Perf Month37.12%
Income-49.30M PEG- EPS next Q-0.34 Inst Own62.80% Short Float2.54% Perf Quarter150.18%
Sales- P/S- EPS this Y-25.10% Inst Trans-0.03% Short Ratio0.39 Perf Half Y33.77%
Book/sh1.75 P/B4.07 EPS next Y-4.30% ROA-68.50% Target Price- Perf Year32.04%
Cash/sh2.34 P/C3.04 EPS next 5Y- ROE-100.90% 52W Range1.48 - 8.05 Perf YTD22.72%
Dividend- P/FCF- EPS past 5Y2.20% ROI- 52W High-11.43% Beta2.25
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low381.76% ATR0.65
Employees20 Current Ratio14.50 Sales Q/Q- Oper. Margin- RSI (14)60.42 Volatility9.44% 11.42%
OptionableYes Debt/Eq0.28 EPS Q/Q49.40% Profit Margin- Rel Volume0.39 Prev Close6.76
ShortableYes LT Debt/Eq0.26 EarningsAug 06 BMO Payout- Avg Volume1.46M Price7.13
Recom1.50 SMA2012.27% SMA5035.28% SMA20050.13% Volume565,715 Change5.47%
May-12-20Initiated Oppenheimer Outperform $12
Dec-04-18Initiated Citigroup Buy $23
Sep-26-18Reiterated Cantor Fitzgerald Overweight $23 → $30
Sep-13-18Initiated Janney Buy
Jan-26-18Initiated Seaport Global Securities Buy $13
Sep-26-16Initiated H.C. Wainwright Buy $18
Jul-01-16Initiated Stifel Buy $16
Jul-01-15Initiated Canaccord Genuity Buy $16
Mar-25-15Initiated Chardan Capital Markets Buy $16
Mar-20-15Reiterated H.C. Wainwright Buy $13 → $14
Nov-18-14Initiated H.C. Wainwright Buy $13
Jun-19-14Initiated Aegis Capital Buy $35
Aug-06-20 10:09AM  
07:00AM  
Aug-04-20 10:07AM  
08:00AM  
Jul-30-20 08:00AM  
Jul-14-20 08:00AM  
04:32AM  
Jul-13-20 04:05PM  
Jul-07-20 09:28PM  
08:00AM  
Jul-03-20 11:15AM  
Jun-22-20 12:00PM  
Jun-18-20 10:12AM  
Jun-15-20 08:00AM  
Jun-10-20 08:37PM  
Jun-07-20 06:28PM  
Jun-04-20 08:00AM  
Jun-03-20 09:04AM  
08:00AM  
May-27-20 09:49AM  
May-20-20 05:24PM  
08:12AM  
07:00AM  
01:48AM  
May-19-20 04:05PM  
May-15-20 08:53AM  
May-14-20 10:14AM  
May-13-20 12:00PM  
08:17AM  
May-07-20 07:00AM  
Apr-16-20 06:35AM  
Apr-15-20 09:47AM  
Apr-14-20 08:00AM  
Apr-01-20 01:42AM  
Mar-24-20 12:00PM  
08:00AM  
Mar-18-20 06:13AM  
Mar-12-20 07:00AM  
06:59AM  
Mar-05-20 08:00AM  
Mar-03-20 08:00AM  
Feb-24-20 08:00AM  
Feb-11-20 08:00AM  
Jan-28-20 08:00AM  
Jan-21-20 08:00AM  
Jan-14-20 08:00AM  
Dec-21-19 07:07AM  
Dec-19-19 08:00AM  
Dec-13-19 03:07PM  
Dec-10-19 05:42PM  
Dec-03-19 12:42PM  
07:59AM  
07:13AM  
07:00AM  
Dec-02-19 04:01PM  
Nov-12-19 08:00AM  
Nov-07-19 07:00AM  
Nov-01-19 08:00AM  
Oct-31-19 07:00AM  
Oct-30-19 04:01PM  
Oct-21-19 08:02AM  
Oct-13-19 04:33PM  
Oct-07-19 08:00AM  
Sep-26-19 08:00AM  
Sep-25-19 09:50AM  
08:00AM  
Sep-24-19 08:00AM  
Sep-12-19 02:15AM  
Sep-06-19 11:18AM  
Aug-30-19 11:24PM  
Aug-28-19 08:30AM  
Aug-09-19 06:56PM  
Aug-08-19 07:00AM  
Jul-05-19 12:29PM  
Jun-25-19 09:26AM  
07:39AM  
07:00AM  
Jun-24-19 04:30PM  
May-30-19 08:00AM  
May-17-19 07:21PM  
May-09-19 03:23PM  
07:00AM  
May-02-19 08:00AM  
Apr-30-19 08:00AM  
Apr-09-19 08:00AM  
Apr-02-19 08:00AM  
Mar-27-19 05:09PM  
10:00AM  
Mar-26-19 01:14PM  
11:57AM  
10:37AM  
09:41AM  
07:51AM  
07:46AM  
07:00AM  
Mar-25-19 04:01PM  
Mar-13-19 10:35AM  
02:02AM  
Mar-08-19 12:12PM  
07:00AM  
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerJul 09Buy4.253,200,00013,600,0006,285,458Jul 13 04:30 PM
DOUGLAS RICHARDDirectorMar 16Buy2.7540,000110,000125,000Mar 17 04:38 PM
Brady Todd CPresident and CEODec 16Buy5.1020,000101,908652,216Dec 18 07:35 AM
Brady Todd CPresident and CEOSep 30Buy5.688,71049,483632,216Oct 02 07:36 AM
Brady Todd CPresident and CEOSep 23Buy5.818,68050,433623,506Sep 25 07:40 AM
Brady Todd CPresident and CEOSep 18Buy5.9114,28884,465614,826Sep 20 07:37 AM
Bronstein BenDirectorSep 17Buy5.851,7009,94518,644Sep 19 04:23 PM
Brady Todd CPresident and CEOSep 16Buy6.033,00018,090591,991Sep 17 07:35 AM
DOUGLAS RICHARDDirectorSep 13Buy6.005,00030,00085,000Sep 17 07:36 AM
Brady Todd CPresident and CEOSep 13Buy5.7910,00057,900588,991Sep 17 07:35 AM
JOYCE MARTIN JOSEPHDirectorSep 12Buy5.861,7009,96419,644Sep 16 04:15 PM
DOUGLAS RICHARDDirectorSep 12Buy6.0310,00060,27680,000Sep 13 07:54 AM
DOUGLAS RICHARDDirectorSep 11Buy5.7510,00057,52970,000Sep 13 07:54 AM
Brady Todd CPresident and CEOSep 10Buy5.3910,00053,937578,991Sep 11 04:05 PM
DOUGLAS RICHARDDirectorSep 10Buy5.0910,00050,85760,000Sep 11 04:05 PM
DOUGLAS RICHARDDirectorSep 09Buy4.9110,00049,10650,000Sep 11 04:05 PM
Brady Todd CPresident and CEOSep 09Buy4.8910,00048,887568,991Sep 11 04:05 PM
Clark David JChief Medical OfficerSep 06Buy5.065,00025,31117,878Sep 10 05:01 PM
Reed JoshuaChief Financial OfficerSep 05Buy4.713,20015,07235,774Sep 09 04:38 PM
McMullin DavidChief Commerical OfficerSep 05Buy4.684,32920,2606,148Sep 09 04:37 PM